

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 1548)**

## **OVERSEAS REGULATORY ANNOUNCEMENT LEGEND BIOTECH ANNOUNCES NEW APPOINTMENT TO THE BOARD OF DIRECTORS**

This announcement is made by the board of directors (the “**Board**”) of Genscript Biotech Corporation (the “**Company**”) pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Legend Biotech Corporation (“**Legend Biotech**”), a non-wholly owned subsidiary of the Company, whose shares are listed by way of American Depositary Shares on the Nasdaq Global Select Market in the United States, has filed a Form 6-K with the United States Securities and Exchange Commission (the “**SEC**”) on 8 August 2024 (New York time) (before the opening of trading hours on 9 August 2024 in Hong Kong) in relation to the appointment of Peter Salovey Ph.D. as a new independent director to Legend Biotech’s board of directors, effective as of August 9 2024. (“**Appointment**”).

For details of the Appointment, please refer to the attached Form 6-K. The attached is the full Form 6-K as published on the SEC’s website available at <https://www.sec.gov/Archives/edgar/data/1801198/000117184324004605/0001171843-24-004605-index.html>.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

**Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.**

By Order of the Board  
**Genscript Biotech Corporation**  
**MENG Jiange**  
*Chairman and Executive Director*

Hong Kong, 9 August 2024

*As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Director is Dr. Wang Luquan; and the Independent non-executive Directors are Mr. Dai Zumian, Mr. Pan Juan, Mr. Cheung Yiu Leung Andy and Dr. Shi Chenyang.*

*\* For identification purposes only*

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES  
EXCHANGE ACT OF 1934**

**Date of Report: August 8, 2024**

Commission File Number: **001-39307**

**Legend Biotech Corporation**

(Translation of registrant's name into English)

**2101 Cottontail Lane Somerset, New Jersey 08873**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F ☒ Form 40-F ☐

---

## **Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors**

On August 8, 2024, the Board of Directors of Legend Biotech Corporation (“Legend Biotech”) appointed Peter Salovey, Ph.D., to Legend Biotech’s Board of Directors, effective as of August 9, 2024. Dr. Salovey will serve as a Class III director, with an initial term until Legend Biotech’s 2026 annual general meeting of shareholders.

Dr. Salovey is the Chris Argyris Professor of Psychology and was the twenty-third president of Yale University, serving as President from July 2013 to June 2024. As President, Dr. Salovey led the development of new programs and facilities across the schools and departments of Yale, including restructuring and expanding the Faculty of Arts and Sciences and the School of Engineering and Applied Science, launching the Jackson School of Global Affairs, transitioning the Yale School of Public Health into a self-supporting independent school, and opening two new residential colleges to expand the undergraduate student population by 15%. Before becoming president, Dr. Salovey served as Yale’s provost, dean of Yale College, and dean of the Yale Graduate School of Arts and Sciences. Dr. Salovey also played key roles in multiple Yale healthcare programs, including the Yale Center for Emotional Intelligence, which he founded; the Center for Interdisciplinary Research on AIDS; and the Cancer Prevention Research Program of the Yale Cancer Center. The research conducted in his laboratory focused on health communication and human emotion. Dr. Salovey received his an A.B. (psychology) and A.M. (sociology) from Stanford University and earned an M.S., M.Phil., and Ph.D. in psychology from Yale University. He completed his internship in clinical health psychology at the West Haven Veterans Administration Medical Center and is a licensed clinical psychologist in the State of Connecticut.

On August 9, 2024, in accordance with the Company’s non-employee director compensation policy, Dr. Salovey will be granted a restricted share unit award for a number of shares equivalent to \$350,000 divided by one half of the closing price of the Company’s ADS on the date of grant, which will be granted pursuant to, and will otherwise be subject to the terms and conditions of the Company’s Restricted Share Unit Incentive Plan (the “RSU Plan”) and the Company’s form of Restricted Share Unit Agreement, with vesting over a period of three years as follows: (i) one-third of the total shares will vest on the first anniversary of the grant date and (ii) one-twelfth of the total shares shall vest quarterly thereafter over the remaining two years of the vesting period, subject to Dr. Salovey’s continued service to the Company through each applicable vesting date. Additionally, Dr. Salovey will be entitled to receive an annual cash retainer of \$75,000 for serving on our board of directors. Dr. Salovey will also enter into the Company’s standard form of indemnification agreement, the form of which is filed as Exhibit 10.2 to the Company’s Registration Statement on Form S-3 (File No. 333-238232) filed with the Securities and Exchange Commission on May 29, 2020.

There are no arrangements or understandings between Dr. Salovey and any other persons pursuant to which Dr. Salovey was appointed as a director, and there are no related-party transactions in which Dr. Salovey has an interest requiring disclosure.

On August 8, 2024, Legend Biotech issued a press release announcing the appointment of Dr. Salovey, which is attached to this Form 6-K as Exhibit 99.1.

This report on Form 6-K is hereby incorporated herein by reference in the registration statements of Legend Biotech on Form F-3 (Nos. 333-278050, 333-257625, and 333-272222) and Form S-8 (No. 333-239478), to the extent not superseded by documents or reports subsequently filed.

### **EXHIBIT INDEX**

<b>Exhibit</b>	<b>Title</b>
----------------	--------------

<a href="#"><u>99.1</u></a>	<a href="#"><u>Press Release, dated August 8, 2024</u></a>
-----------------------------	------------------------------------------------------------

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Legend Biotech Corporation**

(Registrant)

Date: August 8, 2024

/s/ Ying Huang

Ying Huang, Ph.D.  
Chief Executive Officer



## **Legend Biotech Appoints Peter Salovey Ph.D., to its Board of Directors**

**SOMERSET, NJ – August 8, 2024** – Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Peter Salovey, Ph.D., President emeritus of Yale University, to its Board of Directors. Dr. Salovey will serve as an independent director, effective August 9.

“We are pleased to welcome Dr. Salovey to the Legend Board,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “Dr. Salovey’s deep experience and wealth of knowledge in medical research and public health will be invaluable to Legend and offer a new and diverse perspective. We look forward to his insights and contributions to the strategic decisions that will strengthen and drive further growth for our Company.”

Dr. Salovey is the Chris Argyris professor of Psychology and was the twenty-third president of Yale University, serving as President from July 2013 to June 2024. As President, Dr. Salovey led the development of new programs and facilities across the schools and departments of Yale, including restructuring and expanding the Faculty of Arts and Sciences and the School of Engineering and Applied Science, launching the Jackson School of Global Affairs, transitioning the Yale School of Public Health into a self-supporting independent school, and opening two new residential colleges to expand the undergraduate student population by 15%. Before becoming president, Dr. Salovey served as Yale’s provost, dean of Yale College, and dean of the Yale Graduate School of Arts and Sciences. Dr. Salovey also played key roles in multiple Yale healthcare programs, including the Yale Center for Emotional Intelligence, which he founded; the Center for Interdisciplinary Research on AIDS; and the Cancer Prevention Research Program of the Yale Cancer Center. The research conducted in his laboratory focused on health communication and human emotion.

“There has been a lot of momentum within the CAR-T space over the past several years, as it has the potential to transform the treatment paradigm for multiple myeloma patients,” said Dr. Salovey. “I am honored by the opportunity to be part of the Legend Board and collaborate with such a high-caliber organization and leadership team working to bring innovative therapies to patients with debilitating and life-threatening diseases.”

Dr. Salovey received his an A.B. (psychology) and A.M. (sociology) from Stanford University and earned an M.S., M.Phil., and Ph.D. in psychology from Yale University. He completed his internship in clinical health psychology at the West Haven Veterans Administration Medical Center and is a licensed clinical psychologist in the State of Connecticut.

### **ABOUT LEGEND BIOTECH**

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell (gd T) and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more at [www.legendbiotech.com](http://www.legendbiotech.com) and follow us on [X \(formerly Twitter\)](#) and [LinkedIn](#).

**INVESTOR CONTACT:**

Jessie Yeung  
Tel: (732) 956-8271  
[jessie.yeung@legendbiotech.com](mailto:jessie.yeung@legendbiotech.com)

**PRESS CONTACT:**

Mary Ann Ondish  
Tel: (914) 552-4625  
[media@legendbiotech.com](mailto:media@legendbiotech.com)